Immunohistochemistry analysis of a panel of prostate cancer xenografts revealed higher CDC7 protein expression in xenografts lacking AR expression and exhibiting a neuroendocrine phenotype, such as the LNCaP Trop2 oncogene driven NEPC model (TD-NEPC)32 and NCI-H660, compared to the adenocarcinoma cell lines C4-2 and LNCaP (Fig. 1G). This evidence concerns the gene AR and prostate cancer.